Technical Chemicals and Products, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Firm will relocate its Pharmetrix division and close its transdermal R&D facility in Menlo Park, California upon expiration of the lease next month as part of an ongoing program to increase operating efficiency, the company announces May 19. The move comes one week after retaining Janssen/Meyers Associates, LP for investment banking services and consulting on corporate finance and strategic transactions. TCPI will maintain associated patents and continue development of its transdermal drug delivery and skin permeation technologies at corporate headquarters in Pompano Beach, Florida. The firm says it is currently discussing development of the Pharmetrix product and patent portfolios with several pharmaceutical companies